\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

News and Events

For additional information, please contact info@trovagene.com. or call 1-858-952-7593

Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib CNA Article

Please see write-up on Trovagene by CNA. Click Here to Read Article